Termeer: "It can't go on forever"

Genzyme's CEO spent a good part of Monday burnishing the prospects of their experimental MS drug alemtuzumab, and thereby the value of the big biotech. With Sanofi so far unwilling to budge from its $69 offer, and Genzyme just as insistent on refusing to entertain such a price, Henri Termeer was limited to making fresh enthusiastic noises about a possible contingent value rights deal. But for now there's nothing new on prospective talks with Sanofi. "Clearly," said Termeer, "we will have conversations at the right moment...It can't go on forever."Story

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.